TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02994953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241 (MTD)
Description: Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (Expansion cohort)
Description: Participants in the expansion cohorts received Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
Study: NCT03833271

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine, Immune function
Description: Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine, Immune function
Description: Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine, Immune function
Description: Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
Study: NCT02252549

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPIES+WLI assisted TURB
Study: NCT03962413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Approaches To Maxillary Sinus
Description: The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Approaches To Maxillary Sinus
Description: The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Approaches To Maxillary Sinus
Description: The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach.
Study: NCT00329836

Intervention type: OTHER
Intervention: There are no interventions in the observational study. The symptom of allodynia was measured.
Description: No intervention. Description of allodynia testing appears elsewhere in this document
Study: NCT01427829

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Computer-assisted Psychosocial Risk Assessment (CaPRA)
Description: The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted Psychosocial Risk Assessment (CaPRA)
Description: The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
Study: NCT03449186

Intervention type: OTHER
Intervention: Saliva collection

Intervention type: OTHER
Intervention: Saliva collection

Intervention type: OTHER
Intervention: GCF collection
Study: NCT02252549

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WLI assisted TURB
Study: NCT03449186

Intervention type: OTHER
Intervention: GCF collection
Study: NCT01957033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education once/week for 6 weeks
Description: Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education once/week for 6 weeks
Description: Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education once/week for 6 weeks
Description: Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and education twice/week for 6 weeks
Description: Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
Study: NCT01742910

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraocular lens implantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraocular lens implantation
Study: NCT04297124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90009
Description: 0.6 mg \[ 14C\]-CC-90009 administered IV as a single dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]
Description: A single dose of \[ 14C\]-CC-90009 will contain approximately 2 µCi of radioactivity.
Study: NCT01694459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Description: Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose heparin
Description: Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
Study: NCT02583100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Feedback
Description: (1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Feedback
Description: (1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
Study: NCT00359203

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dual chamber pacemeker
Study: NCT03153644

Intervention type: BEHAVIORAL
Intervention: Interview
Description: 1 hour semi-structured

Intervention type: BEHAVIORAL
Intervention: Interview
Description: 1 hour semi-structured

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Field Observation
Study: NCT00913991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Training
Description: Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Training
Description: Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
Study: NCT00873535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
Study: NCT03649659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: SDF will be applied twice during the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is being compared to the SDF and will also be applied twice
Study: NCT00359203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual chamber pacemeker
Study: NCT02912247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection
Description: human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
Study: NCT04441658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline containing human albumin will be infused to the control group
Study: NCT03453944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VentFree prototype (VF03-K) active stimulation
Description: Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VentFree prototype (VF03-K) sham stimulation
Description: Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
Study: NCT04900194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based sexual counseling
Description: Mindfulness-based sexual counseling was planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session lasted 30-40 minutes on average. The sessions were carried out individually by determining the appropriate days of pregnant women in the pregnancy class.In the study, the meditation techniques of the Mindfulness Therapy constituted the backbone/framework of the psychoeducation program. Body and breath, body scanning, mindfulness movement and three-minute respiration techniques were practiced during the psychoeducation program, practically every session in accordance with the researchers' directives.
Study: NCT01411696

Intervention type: DRUG
Intervention: dexamethasone intravitreal implant 0.7 mg
Description: Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
Study: NCT02233309

Intervention type: OTHER
Intervention: Monitoring of pressures during caudal anesthesia
Description: The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
Study: NCT02328755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-IFN-α

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplant (HCT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
Study: NCT03125681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
Study: NCT04483011

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RiaGev
Description: Dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RiaGev
Description: Dietary supplementation
Study: NCT03125681

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
Study: NCT03481660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT02808195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinect-based constraint-induced therapy
Study: NCT03115853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Description: Aliskiren 150 mg daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Description: Aliskiren 150 mg daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet for Aliskerin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet for Aliskerin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ
Description: HCTZ 25mg every day for 18 weeks
Study: NCT03864211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Description: Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to five target lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation.
Study: NCT03115853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ
Description: HCTZ 25mg every day for 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Description: Aliskiren 300 mg for 4 weeks
Study: NCT02801279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional bilateral arm training
Description: The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinect-based bilateral arm training
Description: The conventional bilateral arm training focuses activities that required the use of both hands.
Study: NCT02944357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo cystectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Cell-Derived Vaccine Therapy
Description: Given AGS-003-BLD ID
Study: NCT02241876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Study: NCT03920293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Concentrated sterile, preservative-free aqueous solution (10 milligrams \[mg\]/milliliter \[mL\]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
Study: NCT00651495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient decision aids for chronic conditions
Description: Videos providing comprehensive information about chronic disease management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient decision aids for chronic conditions
Description: Videos providing comprehensive information about chronic disease management
Study: NCT05499208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giving side position with patient turning and movement system
Description: To provide effective breastfeeding by placing the mother in position.
Study: NCT00799487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONCERTA (methylphenidate HCl) or placebo
Description: Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONCERTA (methylphenidate HCl) or placebo
Description: Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
Study: NCT01052051

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 2000 IU/daily
Study: NCT03606707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: intra-articular steroid injection for atlantoaxial joint
Study: NCT00954798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
Study: NCT01052051

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 2000 IU/daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Calcium carbonate 1500mg / daily
Study: NCT00954798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21
Study: NCT03742999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy program
Description: this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Link Upper Limb Exerciser
Description: The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: physical therapy program and ELink Upper Limb Exerciser
Description: physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months